Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI354 vs Chemotherapy in Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06834672Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of IBI354 in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Innovent Biologics. Started Mar 2025; status: active, not recruiting.
02
Drugs
IBI354
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06834672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834672.